The Union Ministry of Health and Family Welfare has notified the inclusion of the drug Pregabalin under Schedule H1 of the Drugs Rules, 1945. Issued via Gazette Notification G.S.R. 377(E), this regulatory reclassification upgrades Pregabalin from its previous Schedule H status. The decision follows extensive reports from several state health departments, law enforcement agencies, and the Food and Drugs Administration (FDA) of Punjab regarding the widespread non-medical abuse of the drug, particularly among youth and individuals dealing with opioid substance-use disorders. The step tightens control over the manufacturing, supply chain, and retail distribution of the drug across India.
Clinical Profile and Therapeutic Uses of Pregabalin
Pregabalin belongs to a specific class of neurological medications known as gabapentinoids. It acts directly on the central nervous system to modulate overactive nerve signals.
Primary Approved Medical Uses
- Neuropathic Pain: Management of chronic nerve pain associated with diabetic peripheral neuropathy, spinal cord injuries, and post-herpetic neuralgia.
- Fibromyalgia: Treatment of widespread musculoskeletal pain accompanied by fatigue, sleep, and memory issues.
- Partial Seizures: Used as an adjunctive therapy for adults experiencing partial-onset seizures.
- Generalized Anxiety Disorder (GAD): Prescribed in specific clinical settings to manage chronic anxiety symptoms.
Pharmacology of Abuse
While highly effective for clinical indications, Pregabalin can induce sedative, euphoric, and dissociative effects when consumed in high, unauthorized doses (typically 150 mg and 300 mg formulations). Users quickly develop a psychological and physical dependence on the drug, which increases the risk of accidental overdose, especially when mixed with other central nervous system depressants like opioids or alcohol.
Statutory Provisions and Compliance Under Schedule H1
The inclusion of Pregabalin under Schedule H1 introduces rigorous tracking and labeling mechanisms designed to eliminate over-the-counter (OTC) sales and black-market trafficking.
Requirements for Retailers and Pharmacists
- Valid Prescription Access: The drug can be dispensed exclusively against a fresh, valid prescription issued by a Registered Medical Practitioner (RMP).
- Mandatory Sales Register: Retailers must maintain a separate, dedicated register to record the name and address of the prescriber, the patient name, the quantity sold, and the exact date of the transaction.
- Three-Year Record Retention: This physical or digital sales register must be preserved for a minimum period of three years and remains subject to spot inspections by drug inspectors.
Requirements for Manufacturers and Packaging
- The Red “Rx” Identifier: Packaging must prominently display a distinct red “Rx” symbol on the top left corner.
- Mandatory Warning Text: Product labels must carry a specialized warning box containing text specified under the Drugs Rules.
| Mandatory Label Warning Text |
| SCHEDULE H1 PRESCRIPTION DRUG-CAUTION: – It is dangerous to take this preparation except in accordance with the medical advice. – Not to be sold by retail without the prescription of a Registered Medical Practitioner. |
Enforcement and Penal Provisions
Any unauthorized distribution, failure to document sales records, or lack of proper packaging warnings will invite immediate administrative and criminal prosecution. Violations attract strict penalties, license cancellations, and imprisonment under the provisions of the parent legislation, the Drugs and Cosmetics Act, 1940.
Comparative Overview of Drug Schedules in India
The classification of medicines under the Drugs Rules, 1945 determines how easily a compound can be accessed by the public and monitored by regulators.
| Drug Schedule | Regulatory Focus | Key Compliance Requirements | Examples of Drugs |
| Schedule H | Standard Prescription Drugs | Cannot be sold without an RMP prescription; no mandatory separate sales register. | Most antibiotics, painkillers, anti-diabetics |
| Schedule H1 | High-Risk Misuse Medications | Requires an RMP prescription; mandatory separate register; strict three-year record keeping. | Third/Fourth-gen antibiotics, Anti-TB drugs, Pregabalin |
| Schedule X | Narcotic and Psychotropic Drugs | Requires special duplicate prescriptions; one copy stored by the chemist; locked storage required. | Ketamine, Amphetamines, Phenobarbital |
| Schedule G | Medical Supervision Drugs | Must carry a label warning stating it is dangerous to take without medical supervision. | Metformin, Antihistamines, Hormones |
IASPOINT Booster Facts for UPSC
- Parent Legislation: The Drugs Rules, 1945, which derive their statutory authority directly from the parent Act—The Drugs and Cosmetics Act, 1940.
- Apex Advisory Body: The inclusion of Pregabalin under Schedule H1 was finalized following statutory technical recommendations from the Drugs Technical Advisory Board (DTAB).
- Introduction of Schedule H1: Schedule H1 was originally inserted into the Drugs Rules in 2013 primarily to check the over-the-counter sale of high-end antibiotics and curb the growing threat of Antimicrobial Resistance (AMR).
- Administrative Ministry: The Central Drugs Standard Control Organisation (CDSCO), operating under the Ministry of Health and Family Welfare, serves as the central drug regulatory authority responsible for executing these schedules.
- Global Regulatory Alignment: With this reclassification, India aligns its domestic policy with international standards; nations like the United Kingdom have already classified Pregabalin as a controlled substance due to addiction risks.